These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis. Bär S; Rommelaere J; Nüesch JP PLoS Pathog; 2015 Mar; 11(3):e1004703. PubMed ID: 25742010 [TBL] [Abstract][Full Text] [Related]
8. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256 [TBL] [Abstract][Full Text] [Related]
9. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859 [TBL] [Abstract][Full Text] [Related]
10. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J Front Immunol; 2019; 10():1848. PubMed ID: 31440242 [TBL] [Abstract][Full Text] [Related]
11. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. Geletneky K; Herrero Y Calle M; Rommelaere J; Schlehofer JR J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):327-30. PubMed ID: 16316394 [TBL] [Abstract][Full Text] [Related]
13. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410 [TBL] [Abstract][Full Text] [Related]
14. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells. Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212 [TBL] [Abstract][Full Text] [Related]
16. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA Viruses; 2021 May; 13(6):. PubMed ID: 34071585 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558 [TBL] [Abstract][Full Text] [Related]
18. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. Bhat R; Rommelaere J BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745 [TBL] [Abstract][Full Text] [Related]
20. Novel oncolytic viruses: riding high on the next wave? Stanford MM; Bell JC; Vähä-Koskela MJ Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]